Logo

Thermo Fisher Scientific Oncomine Childhood Cancer Research Assay

Apr 16, 2018

Thermo Fisher Scientific has launched the Oncomine Childhood Cancer Research Assay, a next-generation sequencing panel developed in collaboration with Children's Hospital Los Angeles that specifically targets mutations associated with pediatric and young adult cancers. The assay combines specific mutations, gene amplifications, and fusions over 203 genes representing multiple gene classes, and 1,700 fusion transcripts in two DNA and two RNA pools. The assay is designed to integrate with the Ion Chef system for automated library preparation and amplification, as well as the Ion GeneStudio S5 system and Ion Reporter for bioinformatics and reporting.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.